vs
BIOLIFE SOLUTIONS INC（BLFS）与LivaNova PLC（LIVN）财务数据对比。点击上方公司名可切换其他公司
LivaNova PLC的季度营收约是BIOLIFE SOLUTIONS INC的19.2倍（$360.9M vs $18.8M）。BIOLIFE SOLUTIONS INC净利率更高（58.9% vs 8.6%，领先50.4%）。BIOLIFE SOLUTIONS INC同比增速更快（24.3% vs 12.1%）。过去两年LivaNova PLC的营收复合增速更高（10.6% vs 1.0%）
BIOLIFE SOLUTIONS INC专注于开发生物保存产品及冷链管理解决方案，服务于细胞与基因治疗、生物制药及再生医学领域，产品涵盖低温保存培养基、自动化解冻系统、温度监测工具，为全球相关企业、科研机构及临床实验室提供支持。
LivaNova PLC是一家深耕医疗设备领域的企业，总部位于英国，核心业务为研发心脏外科及神经调控类医疗设备。该公司由美国Cyberonics公司与意大利Sorin公司于2015年以27亿美元对价合并成立，目前在纳斯达克挂牌交易，股票代码为LIVN。
BLFS vs LIVN — 直观对比
营收规模更大
LIVN
是对方的19.2倍
$18.8M
营收增速更快
BLFS
高出12.2%
12.1%
净利率更高
BLFS
高出50.4%
8.6%
两年增速更快
LIVN
近两年复合增速
1.0%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $18.8M | $360.9M |
| 净利润 | $11.1M | $30.9M |
| 毛利率 | — | 65.2% |
| 营业利润率 | 7.2% | 11.8% |
| 净利率 | 58.9% | 8.6% |
| 营收同比 | 24.3% | 12.1% |
| 净利润同比 | -11.1% | -44.7% |
| 每股收益（稀释后） | $0.23 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLFSLIVN
| Q4 25 | $18.8M | $360.9M | ||
| Q3 25 | $28.1M | $357.8M | ||
| Q2 25 | $25.4M | $352.5M | ||
| Q1 25 | $23.9M | $316.9M | ||
| Q4 24 | $15.1M | $321.8M | ||
| Q3 24 | $21.4M | $318.1M | ||
| Q2 24 | $19.7M | $318.6M | ||
| Q1 24 | $18.4M | $294.9M |
净利润BLFSLIVN
| Q4 25 | $11.1M | $30.9M | ||
| Q3 25 | $621.0K | $26.8M | ||
| Q2 25 | $-15.8M | $27.2M | ||
| Q1 25 | $-448.0K | $-327.3M | ||
| Q4 24 | $12.5M | $55.9M | ||
| Q3 24 | $-1.7M | $33.0M | ||
| Q2 24 | $-20.7M | $16.3M | ||
| Q1 24 | $-10.2M | $-41.9M |
毛利率BLFSLIVN
| Q4 25 | — | 65.2% | ||
| Q3 25 | — | 68.4% | ||
| Q2 25 | — | 67.8% | ||
| Q1 25 | — | 69.7% | ||
| Q4 24 | — | 68.2% | ||
| Q3 24 | — | 70.8% | ||
| Q2 24 | — | 68.7% | ||
| Q1 24 | — | 70.3% |
营业利润率BLFSLIVN
| Q4 25 | 7.2% | 11.8% | ||
| Q3 25 | -0.3% | 15.1% | ||
| Q2 25 | -65.5% | 15.4% | ||
| Q1 25 | -5.1% | 15.3% | ||
| Q4 24 | 3.6% | 11.5% | ||
| Q3 24 | -2.0% | 11.2% | ||
| Q2 24 | -6.6% | 12.6% | ||
| Q1 24 | -17.9% | 5.5% |
净利率BLFSLIVN
| Q4 25 | 58.9% | 8.6% | ||
| Q3 25 | 2.2% | 7.5% | ||
| Q2 25 | -62.3% | 7.7% | ||
| Q1 25 | -1.9% | -103.3% | ||
| Q4 24 | 82.5% | 17.4% | ||
| Q3 24 | -8.0% | 10.4% | ||
| Q2 24 | -105.1% | 5.1% | ||
| Q1 24 | -55.4% | -14.2% |
每股收益（稀释后）BLFSLIVN
| Q4 25 | $0.23 | $0.57 | ||
| Q3 25 | $0.01 | $0.49 | ||
| Q2 25 | $-0.33 | $0.50 | ||
| Q1 25 | $-0.01 | $-6.01 | ||
| Q4 24 | $0.27 | $1.04 | ||
| Q3 24 | $-0.04 | $0.60 | ||
| Q2 24 | $-0.45 | $0.30 | ||
| Q1 24 | $-0.22 | $-0.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.0M | $635.6M |
| 总债务越低越好 | $5.0M | $376.1M |
| 股东权益账面价值 | $371.9M | $1.2B |
| 总资产 | $405.9M | $2.6B |
| 负债/权益比越低杠杆越低 | 0.01× | 0.31× |
8季度趋势，按日历期对齐
现金及短期投资BLFSLIVN
| Q4 25 | $33.0M | $635.6M | ||
| Q3 25 | $29.5M | $646.1M | ||
| Q2 25 | $31.9M | $593.6M | ||
| Q1 25 | $66.9M | $738.4M | ||
| Q4 24 | $91.5M | $428.9M | ||
| Q3 24 | $24.0M | $346.4M | ||
| Q2 24 | $22.0M | $329.2M | ||
| Q1 24 | $29.7M | $309.2M |
总债务BLFSLIVN
| Q4 25 | $5.0M | $376.1M | ||
| Q3 25 | $7.5M | $434.5M | ||
| Q2 25 | $10.1M | $430.6M | ||
| Q1 25 | $12.9M | $628.2M | ||
| Q4 24 | $15.9M | $627.0M | ||
| Q3 24 | $20.1M | $625.5M | ||
| Q2 24 | $21.1M | $624.5M | ||
| Q1 24 | $24.3M | $623.8M |
股东权益BLFSLIVN
| Q4 25 | $371.9M | $1.2B | ||
| Q3 25 | $353.7M | $1.2B | ||
| Q2 25 | $347.2M | $1.1B | ||
| Q1 25 | $352.6M | $1.0B | ||
| Q4 24 | $348.9M | $1.3B | ||
| Q3 24 | $325.5M | $1.3B | ||
| Q2 24 | $321.4M | $1.2B | ||
| Q1 24 | $333.4M | $1.2B |
总资产BLFSLIVN
| Q4 25 | $405.9M | $2.6B | ||
| Q3 25 | $392.1M | $2.6B | ||
| Q2 25 | $387.2M | $2.5B | ||
| Q1 25 | $395.1M | $2.6B | ||
| Q4 24 | $399.5M | $2.5B | ||
| Q3 24 | $381.7M | $2.5B | ||
| Q2 24 | $375.0M | $2.5B | ||
| Q1 24 | $401.6M | $2.5B |
负债/权益比BLFSLIVN
| Q4 25 | 0.01× | 0.31× | ||
| Q3 25 | 0.02× | 0.38× | ||
| Q2 25 | 0.03× | 0.38× | ||
| Q1 25 | 0.04× | 0.61× | ||
| Q4 24 | 0.05× | 0.47× | ||
| Q3 24 | 0.06× | 0.48× | ||
| Q2 24 | 0.07× | 0.50× | ||
| Q1 24 | 0.07× | 0.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.9M | $82.4M |
| 自由现金流经营现金流 - 资本支出 | — | $50.2M |
| 自由现金流率自由现金流/营收 | — | 13.9% |
| 资本支出强度资本支出/营收 | — | 8.9% |
| 现金转化率经营现金流/净利润 | 0.44× | 2.67× |
| 过去12个月自由现金流最近4个季度 | — | $173.3M |
8季度趋势，按日历期对齐
经营现金流BLFSLIVN
| Q4 25 | $4.9M | $82.4M | ||
| Q3 25 | $6.1M | $85.1M | ||
| Q2 25 | $7.4M | $62.9M | ||
| Q1 25 | $1.7M | $24.0M | ||
| Q4 24 | $1.6M | $78.7M | ||
| Q3 24 | $4.8M | $51.0M | ||
| Q2 24 | $6.5M | $43.4M | ||
| Q1 24 | $-4.5M | $10.0M |
自由现金流BLFSLIVN
| Q4 25 | — | $50.2M | ||
| Q3 25 | — | $62.2M | ||
| Q2 25 | — | $47.8M | ||
| Q1 25 | — | $13.2M | ||
| Q4 24 | — | $68.3M | ||
| Q3 24 | — | $32.8M | ||
| Q2 24 | — | $31.2M | ||
| Q1 24 | — | $3.6M |
自由现金流率BLFSLIVN
| Q4 25 | — | 13.9% | ||
| Q3 25 | — | 17.4% | ||
| Q2 25 | — | 13.6% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | — | 21.2% | ||
| Q3 24 | — | 10.3% | ||
| Q2 24 | — | 9.8% | ||
| Q1 24 | — | 1.2% |
资本支出强度BLFSLIVN
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | — | 4.3% | ||
| Q1 25 | — | 3.4% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | — | 5.7% | ||
| Q2 24 | — | 3.8% | ||
| Q1 24 | — | 2.2% |
现金转化率BLFSLIVN
| Q4 25 | 0.44× | 2.67× | ||
| Q3 25 | 9.83× | 3.18× | ||
| Q2 25 | — | 2.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.13× | 1.41× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 2.65× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLFS
暂无分部数据
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
